Successful treatment of SAPHO syndrome with infliximab: report of two cases
Open Access
- 1 April 2002
- journal article
- letter
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 61 (4) , 375-376
- https://doi.org/10.1136/ard.61.4.375
Abstract
In view of this information we treated two patients affected by refractory SAPHO syndrome with infliximab. Both patients had chest pain limiting normal activity despite adequate treatment with NSAIDs and second line treatment was unsuccessful. Both patients received three intravenous infusions of infliximab (5 mg/kg) at weeks 0, 2, and 6 and were evaluated at baseline, on days 3, 7, and 14, and then every two weeks.Keywords
This publication has 5 references indexed in Scilit:
- SAPHO: Rare or just not recognized?Seminars in Arthritis and Rheumatism, 2000
- Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximabArthritis & Rheumatism, 2000
- Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot studyAnnals of the Rheumatic Diseases, 2000
- SAPHO syndrome: A long-term follow-up study of 120 casesSeminars in Arthritis and Rheumatism, 1999
- The SAPHO syndromeBailliere's Clinical Rheumatology, 1994